BNGO
Bionano Genomics, Inc. (BNGO) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Strong liquidity with a 2.48 current ratio and 1.96 quick ratio supports near-term operating flexibility better than many cash-constrained peers.
Low leverage, with debt-to-equity at 0.21 and net debt to EBITDA negative, reduces refinancing pressure relative to more indebted diagnostics peers.
The company’s cash position can buffer ongoing losses, which is structurally more resilient than peers that must fund commercialization with tighter balance sheets.
Weaknesses
Negative ROIC of -83.8% indicates capital is not yet generating returns, leaving BNGO structurally behind profitable peers in value creation.
The absence of reported operating and gross margins suggests the business remains commercially immature, unlike peers with established recurring revenue economics.
A 67.6-day cash conversion cycle ties up working capital, which weakens efficiency versus peers with faster collection and inventory turnover.
Low leverage does not offset weak operating performance, because balance-sheet strength alone cannot close the gap with peers that already scale profitably.
Opportunities
If BNGO converts its liquidity into sustained commercial adoption, it could narrow the gap with peers that already monetize installed bases more effectively.
Improving working-capital discipline could shorten the cash conversion cycle and free cash for growth, a lever that matters more for smaller peers.
Any future margin disclosure improvement would help demonstrate operating leverage, which is a key differentiator versus peers still viewed as development-stage.
Threats
Persistent negative returns on invested capital raise the risk that peers with stronger execution continue to outcompete BNGO for customer adoption and capital.
If commercialization remains slow, the company may lag peers that have clearer reimbursement, workflow integration, or recurring revenue advantages.
A long cash conversion cycle can amplify funding needs, making BNGO more vulnerable than peers with faster cash generation and tighter working capital.
Limited margin visibility increases execution uncertainty, which can keep the stock structurally discounted versus peers with proven profitability trajectories.
Overall Score
BNGO’s peer positioning is weakened by deeply negative capital returns and limited operating visibility, while liquidity and low leverage only partially offset the gap.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Bionano Genomics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
